Nutra Pharma Corp.
NPHC
$0.00
$0.00100.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -39.99% | -32.45% | -10.26% | 35.71% | 172.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.99% | -32.45% | -10.26% | 35.71% | 172.88% |
| Cost of Revenue | -34.22% | -44.25% | -18.87% | 4.81% | 26.86% |
| Gross Profit | -42.99% | -25.21% | -4.62% | 59.13% | 569.97% |
| SG&A Expenses | -50.58% | -49.98% | -52.52% | -40.49% | 52.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.04% | -49.41% | -49.54% | -36.82% | 49.96% |
| Operating Income | 52.51% | 55.36% | 60.77% | 53.50% | -27.93% |
| Income Before Tax | -162.34% | -144.79% | -147.76% | -117.04% | -70.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -162.34% | -144.79% | -147.76% | -117.04% | -70.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -162.34% | -144.79% | -147.76% | -117.04% | -70.74% |
| EBIT | 52.51% | 55.36% | 60.77% | 53.50% | -27.93% |
| EBITDA | 52.34% | 55.43% | 61.06% | 53.90% | -28.19% |
| EPS Basic | -133.33% | -125.00% | -133.33% | -109.09% | -70.00% |
| Normalized Basic EPS | -100.00% | -100.00% | -100.00% | -100.00% | -50.00% |
| EPS Diluted | -- | -- | 0.00% | -133.33% | -100.00% |
| Normalized Diluted EPS | -100.00% | -100.00% | -100.00% | -100.00% | -75.00% |
| Average Basic Shares Outstanding | 0.57% | 0.50% | 0.73% | 1.40% | 2.25% |
| Average Diluted Shares Outstanding | -43.24% | -50.64% | -50.63% | -55.66% | 20.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |